Positive Phase I data for Ebola vaccine regimen published

Positive data from a Phase I trial of a preventative Ebola vaccine regimen have been published in the Journal of the American Medical Association.

The study, which was led by the Oxford Vaccine Group at the University of Oxford Department of Paediatrics in the UK, tested a vaccine regimen containing two components based on AdVac technology from Crucell Holland, a Janssen a subsidiary of Johnson and Johnson (NYSE: JNJ), and MVA-BN technology from Denmark's (Bavarian Nordic(OMX: BAVA).

The results suggest the regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse effects.